je.st
news
Lilly announces detailed results from two Phase III studies testing...
2014-06-18 12:50:18| Biotech - Topix.net
Eli Lilly and Company has released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with a lower risk for hypoglycemia .1,2 Dulaglutide is an investigational glucagon-like peptide-1 receptor agonist being studied for ... (more)
Tags: results
iii
studies
detailed
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||